부광약품
ABOUT BUKWANG
Company Introduction
Vision & Mission
History
Manufacturing Facilities
Subsidiaries & Affiliates
Contact us
R&D
R&D Facilities
Pipeline
Latuda
JM-010
CP-012
Open Innovation
NEWS
IR
Financial Information
IR Reports
ANNUAL REPORT
PRODUCTS
Product Search
ETC
OTC
Health Functional Food
Personal Care Products
HOME
CONTACT US
KR
KR
EN
ABOUT BUKWANG
Company Introduction
Vision & Mission
History
Manufacturing Facilities
Subsidiaries & Affiliates
Contact us
R&D
R&D Facilities
Pipeline
Latuda
JM-010
CP-012
Open Innovation
JaguAhr
Protekt
NEWS
News
IR
Financial Information
IR Reports
ANNUAL REPORT
PRODUCTS
Product Search
ETC
OTC
Health Functional Food
Personal Care Products
NEWS
HOME
NEWS
NEWS
NEWS
ALL
Company news
Product news
R&D news
R&D news | Bukwang Pharmaceuticals Co., Ltd. announces positive Phase ..
Melior Pharmaceuticals I, Inc (Melior) and Bukwang Pharmaceuticals Co., Ltd. (Bu..
2016.06.13
R&D news | Bukwang Pharm. attends Spring Symposium of Korean Academy o..
The RD Department of Bukwang Pharmaceutical Co., Ltd. attended the Spring Sympos..
2016.05.26
R&D news | Bukwang completes Phase IIa clinical trial for novel anti-di..
Bukwang Pharmaceutical Co., Ltd. announced completion of Phase IIa of “MLR-1023”..
2015.12.15
R&D news | Bukwang Pharm. completes Ph 2 clinical trial of JM-010 in S..
Bukwang Pharm. announced today completion of dosing in the proof-of-concept (PoC..
2015.11.16
R&D news | Bukwang granted US patent covering JM-010 for treatment of m..
Bukwang Pharm and its fully owned subsidiary Contera Pharma announced that the U..
2015.11.11
R&D news | Bukwang Pharm’s LID candidate JM-010 receives IND approval f..
Bukwang Pharm. announced that it received IND approval for the Phase 2a clinical..
2015.04.27
6
7
8